Chemotherapy-induced neuropathy (CIN) symptom persistence among individuals with breast cancer: secondary analysis of recruitment data from an interventional trial

Chemotherapy-induced neuropathy (CIN) affects a large proportion of individuals with breast cancer treated with taxane-based chemotherapy agents (up to 80%); however, questions remain regarding long-term prognosis of this debilitating neurologic complication of breast cancer treatment. We being to assess the scope of the problem by performing a point-prevalence estimate among individuals who developed CIN, assessed at a single (variable) timepoint 3+ months post-treatment completion, within this secondary analysis of recruitment data from a clinical intervention trial (NCT05114005). Per IRB-approved HIPAA waiver for purposes of recruitment screening, we surveyed individuals diagnosed with CIN, who completed treatment at least 3 months prior regarding whether their symptoms had resolved or not. We calculated the proportion of respondents with/without persistent CIN symptoms and performed a sensitivity analysis, computing the largest and smallest possible rate of CIN persistence given the number of non-respondents. Additionally, we analyzed potential predictors of persistent CIN from data available per the HIPAA waiver (e.g., age, time since last taxane dose, HbA1C level) in a complete case analysis. Finally, from a self-identifying subset of individuals with unresolved CIN, we assessed incidence of neuromotor dysfunction using an in-person test of postural control. We surveyed 258 individuals (99.2% female). Mean(SD) age=60.5(11.1); time since last taxane exposure=3.25(2.38) years; HbA1C=5.64(0.61). Symptoms persisted for 84.9% [95% CI 78.6%, 89.9%]. Accounting for both the non-response sensitivity analysis and statistical uncertainty, we estimate bounds of the CIN persistence rate to be no lower than 50.3% and no higher than 93.3%. Higher HbA1C level was associated with symptom persistence ( p =0.037). Variables not associated included total chemotherapy dose ( p =0.8); race (white vs non-white, p =0.4); age ( p =0.09); and time since last taxane dose ( p =0.8). Of those who attended in-person screening, 86.4% demonstrated neuromotor dysfunction. Within this cohort, CIN symptoms were present in 84.9% of individuals who were surveyed a median of 2.77 [95% CI 0.25 to 9.14] years after completion of taxane treatment for breast cancer. More research is needed to improve successful resolution of CIN symptoms and associated neuromotor dysfunction.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-16
DOI
https://doi.org/10.1186/s13058-026-02385-7
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chemotherapy-induced neuropathy (CIN) symptom persistence among individuals with breast cancer: secondary analysis of recruitment data from an interventional trial

Bhillie D. Luciani, Margaret Elena Gatti-Mays, Lise Worthen‐Chaudhari, Sagar D. Sardesai et al.
3 links
Breast Cancer Research
Cancer Treatment and Pharmacology
article

Chemotherapy-induced neuropathy (CIN) symptom persistence among individuals with breast cancer: secondary analysis of recruitment data from an interventional trial

Bhillie D. Luciani, Margaret Elena Gatti-Mays, Lise Worthen‐Chaudhari, Sagar D. Sardesai, Patrick Schnell, Maryam B. Lustberg, Ashley Pariser Davenport
article en

Abstract

Chemotherapy-induced neuropathy (CIN) affects a large proportion of individuals with breast cancer treated with taxane-based chemotherapy agents (up to 80%); however, questions remain regarding long-term prognosis of this debilitating neurologic complication of breast cancer treatment. We being to assess the scope of the problem by performing a point-prevalence estimate among individuals who developed CIN, assessed at a single (variable) timepoint 3+ months post-treatment completion, within this secondary analysis of recruitment data from a clinical intervention trial (NCT05114005). Per IRB-approved HIPAA waiver for purposes of recruitment screening, we surveyed individuals diagnosed with CIN, who completed treatment at least 3 months prior regarding whether their symptoms had resolved or not. We calculated the proportion of respondents with/without persistent CIN symptoms and performed a sensitivity analysis, computing the largest and smallest possible rate of CIN persistence given the number of non-respondents. Additionally, we analyzed potential predictors of persistent CIN from data available per the HIPAA waiver (e.g., age, time since last taxane dose, HbA1C level) in a complete case analysis. Finally, from a self-identifying subset of individuals with unresolved CIN, we assessed incidence of neuromotor dysfunction using an in-person test of postural control. We surveyed 258 individuals (99.2% female). Mean(SD) age=60.5(11.1); time since last taxane exposure=3.25(2.38) years; HbA1C=5.64(0.61). Symptoms persisted for 84.9% [95% CI 78.6%, 89.9%]. Accounting for both the non-response sensitivity analysis and statistical uncertainty, we estimate bounds of the CIN persistence rate to be no lower than 50.3% and no higher than 93.3%. Higher HbA1C level was associated with symptom persistence ( p =0.037). Variables not associated included total chemotherapy dose ( p =0.8); race (white vs non-white, p =0.4); age ( p =0.09); and time since last taxane dose ( p =0.8). Of those who attended in-person screening, 86.4% demonstrated neuromotor dysfunction. Within this cohort, CIN symptoms were present in 84.9% of individuals who were surveyed a median of 2.77 [95% CI 0.25 to 9.14] years after completion of taxane treatment for breast cancer. More research is needed to improve successful resolution of CIN symptoms and associated neuromotor dysfunction.

Breast Cancer Research
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Yale University (US), The Ohio State University (US)
National Institute on Aging
Good health and well-being
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon